MEA radiotherapy market - Industry Trends and Forecast to 2031
- Published Date: 2022-11-22
- Report ID: 144377
- Pages: 200
-
Format:
Short Description
Middle East and Africa Radiotherapy Market, By Type (External-Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiotherapy/ Radiopharmaceuticals, Others), Product (External Beam Radiotherapy, Internal Radiotherapy Products, Radiotherapy Software, Systemic Radiotherapy & Others), Application (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma, Liver Cancer, Thyroid Cancer, Brain Cancer, Cervical Cancer, Spine Cancer, Others), End User (Hospitals, Radiation Therapy Centers, Specialty Clinics, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait and Rest of the Middle East and Africa), Industry Trends and Forecast to 2029
Market Definition
Radiotherapy is a type of treatment procedure that is mainly used to treat cancer disease by the usage of X-rays and similar forms of radiation technology. The method and procedure of radiotherapy have been advanced in terms of launching new treatment planning software and advanced features-based therapy modalities.
In radiotherapy treatment, high-energy based radiation rays are often used to damage cancer cells and stop them from growing and dividing. External radiation therapy has numerous types of advanced technology which is used in the treatment of cancer. External radiation therapy comprised of three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), proton beam therapy, image-guided radiation therapy (IGRT), stereotactic radiation therapy, and volumetric modulated ARC therapy (VMAT), among others.
Market Segmentation
The Middle East and Africa market is categorized into five notable segments based on type, product, application, end user, and distribution channel.
On the basis of type, the Middle East and Africa radiotherapy market is segmented into external-beam radiation therapy, internal radiation therapy, systemic radiotherapy/radiopharmaceuticals, and others
On the basis of product, the Middle East and Africa radiotherapy market is segmented into external beam radiotherapy, internal radiotherapy products, radiotherapy software, systemic radiotherapy, and others
On the basis of application, the Middle East and Africa radiotherapy market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, lymphoma, liver cancer, thyroid cancer, brain cancer, cervical cancer, spine cancer, and others
On the basis of end user, the Middle East and Africa radiotherapy market is segmented into hospitals, radiation therapy centers, specialty clinics, and others
On the basis of distribution channel, the Middle East and Africa radiotherapy market is segmented into direct tender, retail sales, and others
Market Players
The key market players for the Middle East and Africa radiotherapy market are listed below:
Siemens Healthcare GmbH
Elekta AB (pub)
RaySearch Laboratories
Brainlab
Koninklijke Philips N.V.
General Electric Company
Hitachi LTD.
SIT - S.I.T. Sordina IORT Technologies S.p.A.
Sumitomo Heavy Industries, Ltd.
Xoft, a subsidiary of iCAD, Inc.
ZEISS International
TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF MIDDLE EAST & AFRICA RADIOTHERAPY MARKET 41
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 MULTIVARIATE MODELLING 52
2.7 TYPE LIFELINE CURVE 52
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 MARKET APPLICATION COVERAGE GRID 57
2.12 SECONDARY SOURCES 58
2.13 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 62
4.1 PESTEL ANALYSIS 64
4.2 PORTER'S 5 FORCES 65
5 REGULATIONS 66
5.1 BRACHYTHERAPY DEVICES REGULATIONS: 66
5.2 USE OF SOURCES FOR MANUAL BRACHYTHERAPY. 66
5.3 BRACHYTHERAPY SOURCES ACCOUNTABILITY. 66
5.4 EUROPE MEDICAL AGENCY REGULATION 67
5.5 UK 67
5.6 INDIA: 68
6 MARKET OVERVIEW 69
6.1 DRIVERS 71
6.1.1 GROWING PREVALENCE OF CANCER DISEASE 71
6.1.2 NOVEL TECHNOLOGY IN RADIOTHERAPY FOR CANCER TREATMENT 75
6.1.3 INCREASING ADOPTION OF RADIOTHERAPY DEVICES AND PROCEDURES 76
6.1.4 RISING PREFERENCE FOR NON-SURGICAL PROCEDURES 76
6.2 RESTRAINTS 77
6.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 77
6.2.2 COMPLEX NATURE OF RADIOTHERAPY 77
6.2.3 HIGH COST OF RADIOTHERAPY PROCEDURE 78
6.3 OPPORTUNITIES 78
6.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER TREATMENT 78
6.3.2 GROWING GOVERNMENT INITIATIVES TOWARDS CANCER TREATMENT 81
6.3.3 RISING PATIENTS AWARENESS TOWARDS CANCER TREATMENT 81
6.4 CHALLENGES 82
6.4.1 STRICT REGULATIONS AND STANDARDS FOR APPROVAL AND COMMERCIALIZATION OF RADIOTHERAPY PRODUCTS 82
6.4.2 RISK OF RADIATION EXPOSURE 83
7 IMPACT OF COVID-19 ON MIDDLE EAST & AFRICA RADIOTHERAPY MARKET 84
7.1 IMPACT ANALYSIS ON DEMAND 84
7.2 CONCLUSION 84
8 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY TYPE 85
8.1 OVERVIEW 86
8.2 EXTERNAL-BEAM RADIATION THERAPY 89
8.2.1 IMAGE-GUIDED RADIATION THERAPY (IGRT) 90
8.2.2 PROTON BEAM THERAPY 90
8.2.3 STEREOTACTIC RADIATION THERAPY 90
8.2.4 INTENSITY MODULATED RADIATION THERAPY (IMRT) 90
8.2.5 THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT) 90
8.2.6 VOLUMETRIC MODULATED ARC THERAPY (VMAT) 90
8.2.7 OTHERS 91
8.3 INTERNAL RADIATION THERAPY 91
8.3.1 BRACHYTHERAPY 92
8.3.1.1 HIGH DOSE BRACHYTHERAPY 92
8.3.1.2 LOW DOSE BRACHYTHERAPY 92
8.3.2 SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 92
8.4 SYSTEMIC RADIOTHERAPY/ RADIOPHARMACEUTICALS 93
8.5 OTHERS 93
9 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY PRODUCT 95
9.1 OVERVIEW 96
9.2 EXTERNAL BEAM RADIATION THERAPY 99
9.2.1 LINAC 100
9.2.2 PROTON THERAPY 100
9.2.2.1 SYNCHROTRON 100
9.2.2.2 CYCLOTRON 100
9.2.3 CYBER KNIFE 100
9.2.4 GAMMA KNIFE 101
9.2.5 OTHERS 101
9.3 INTERNAL RADIOTHERAPY PRODUCTS 101
9.3.1 SEEDS 102
9.3.2 ELECTRONIC BRACHYTHERAPY 102
9.3.3 APPLICATORS 102
9.3.4 AFTERLOADERS 102
9.3.5 OTHERS 102
9.4 RADIOTHERAPY SOFTWARE 102
9.4.1 IMAGE GUIDING SOFTWARE 103
9.4.2 TREATMENT PLANNING SOFTWARE 103
9.4.3 PATIENT POSITIONING SOFTWARE 103
9.4.4 DOSAGE PLANNING SOFTWARE 104
9.4.5 OTHERS 104
9.5 SYSTEMIC RADIOTHERAPY 104
9.5.1 ALPHA EMITTERS 105
9.5.2 BETA EMITTERS 105
9.6 OTHERS 105
10 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY APPLICATION 106
10.1 OVERVIEW 107
10.2 BREAST CANCER 111
10.3 LUNG CANCER 112
10.4 PROSTATE CANCER 113
10.5 COLORECTAL CANCER 114
10.6 LYMPHOMA 115
10.7 LIVER CANCER 116
10.8 THYROID CANCER 117
10.9 BRAIN CANCER 117
10.10 CERVICAL CANCER 118
10.11 SPINE CANCER 119
10.12 OTHERS 120
11 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY END USER 121
11.1 OVERVIEW 122
11.2 HOSPITALS 125
11.3 RADIATION THERAPY CENTERS 125
11.4 SPECIALTY CLINICS 126
11.5 OTHERS 127
12 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 128
12.1 OVERVIEW 129
12.2 DIRECT TENDER 132
12.3 RETAIL SALES 132
12.4 OTHERS 133
13 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY REGION 134
13.1 MIDDLE EAST AND AFRICA 135
13.1.1 SOUTH AFRICA 143
13.1.2 SAUDI ARABIA 147
13.1.3 UAE 151
13.1.4 EGYPT 155
13.1.5 ISRAEL 159
13.1.6 KUWAIT 163
13.1.7 REST OF MIDDLE EAST AND AFRICA 167
14 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET: COMPANY LANDSCAPE 168
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 168
15 SWOT ANALYSIS 169
16 COMPANY PROFILE 170
16.1 SIEMENS HEALTHCARE GMBH 170
16.1.1 COMPANY SNAPSHOT 170
16.1.2 REVENUE ANALYSIS 170
16.1.3 COMPANY SHARE ANALYSIS 171
16.1.4 PRODUCT PORTFOLIO 171
16.1.5 RECENT DEVELOPMENT 172
16.2 ELEKTA AB (PUB) 173
16.2.1 COMPANY SNAPSHOT 173
16.2.2 RECENT FINANCIALS 173
16.2.3 COMPANY SHARE ANALYSIS 174
16.2.4 PRODUCT PORTFOLIO 174
16.2.5 RECENT DEVELOPMENT 175
16.3 ACCURAY INCORPORATED 176
16.3.1 COMPANY SNAPSHOT 176
16.3.2 RECENT FINANCIALS 176
16.3.3 COMPANY SHARE ANALYSIS 177
16.3.4 PRODUCT PORTFOLIO 177
16.3.5 RECENT DEVELOPMENT 177
16.4 GENERAL ELECTRIC COMPANY 178
16.4.1 COMPANY SNAPSHOT 178
16.4.2 REVENUE ANALYSIS 178
16.4.3 COMPANY SHARE ANALYSIS 179
16.4.4 PRODUCT PORTFOLIO 179
16.4.5 RECENT DEVELOPMENT 179
16.5 IBA WORLDWIDE 180
16.5.1 COMPANY SNAPSHOT 180
16.5.2 RECENT FINANCIALS 180
16.5.3 COMPANY SHARE ANALYSIS 181
16.5.4 PRODUCT PORTFOLIO 181
16.5.5 RECENT DEVELOPMENT 181
16.6 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG) 182
16.6.1 COMPANY SNAPSHOT 182
16.6.2 REVENUE ANALYSIS 182
16.6.3 PRODUCT PORTFOLIO 183
16.6.4 RECENT DEVELOPMENT 183
16.7 ADVANCED ONCOTHERAPY 184
16.7.1 COMPANY SNAPSHOT 184
16.7.2 PRODUCT PORTFOLIO 184
16.8 ARIANE MEDICAL SYSTEMS LTD 185
16.8.1 COMPANY SNAPSHOT 185
16.8.2 PRODUCT PORTFOLIO 185
16.8.3 RECENT DEVELOPMENT 185
16.9 BRAINLAB 186
16.9.1 COMPANY SNAPSHOT 186
16.9.2 PRODUCT PORTFOLIO 186
16.9.3 RECENT DEVELOPMENT 186
16.10 CANON MEDICAL SYSTEMS CORPORATION 187
16.10.1 COMPANY SNAPSHOT 187
16.10.2 PRODUCT PORTFOLIO 187
16.10.3 RECENT DEVELOPMENT 187
16.11 CIVCO RADIOTHERAPY 188
16.11.1 COMPANY SNAPSHOT 188
16.11.2 PRODUCT PORTFOLIO 188
16.11.3 RECENT DEVELOPMENT 189
16.12 ECKERT & ZIEGLER BEBIG 190
16.12.1 COMPANY SNAPSHOT 190
16.12.2 RECENT FINANCIALS 190
16.12.3 PRODUCT PORTFOLIO 191
16.12.4 RECENT DEVELOPMENT 191
16.13 HITACHI, LTD. 192
16.13.1 COMPANY SNAPSHOT 192
16.13.2 REVENUE ANALYSIS 192
16.13.3 PRODUCT PORTFOLIO 193
16.13.4 RECENT DEVELOPMENT 193
16.14 INTRAOP MEDICAL, INC. 194
16.14.1 COMPANY SNAPSHOT 194
16.14.2 PRODUCT PORTFOLIO 194
16.14.3 RECENT DEVELOPMENT 195
16.15 ISORAY INC. 196
16.15.1 COMPANY SNAPSHOT 196
16.15.2 REVENUE ANALYSIS 196
16.15.3 PRODUCT PORTFOLIO 197
16.15.4 RECENT DEVELOPMENT 197
16.16 KONINKLIJKE PHILIPS N.V. 198
16.16.1 COMPANY SNAPSHOT 198
16.16.2 REVENUE ANALYSIS 198
16.16.3 PRODUCT PORTFOLIO 199
16.16.4 RECENT DEVELOPMENT 199
16.17 MEVION MEDICAL SYSTEMS 200
16.17.1 COMPANY SNAPSHOT 200
16.17.2 PRODUCT PORTFOLIO 200
16.17.3 RECENT DEVELOPMENT 200
16.18 MIRADA MEDICAL LIMITED 201
16.18.1 COMPANY SNAPSHOT 201
16.18.2 PRODUCT PORTFOLIO 201
16.18.3 RECENT DEVELOPMENT 201
16.19 NORDION (CANADA) INC. (A SUBSIDIARY OF SOTERA HEALTH) 202
16.19.1 COMPANY SNAPSHOT 202
16.19.2 REVENUE ANALYSIS 202
16.19.3 PRODUCT PORTFOLIO 203
16.19.4 RECENT DEVELOPMENT 203
16.20 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 204
16.20.1 COMPANY SNAPSHOT 204
16.20.2 PRODUCT PORTFOLIO 204
16.20.3 RECENT DEVELOPMENT 204
16.21 P-CURE 205
16.21.1 COMPANY SNAPSHOT 205
16.21.2 PRODUCT PORTFOLIO 205
16.21.3 RECENT DEVELOPMENT 205
16.22 PROTOM INTERNATIONAL 206
16.22.1 COMPANY SNAPSHOT 206
16.22.2 PRODUCT PORTFOLIO 206
16.22.3 RECENT DEVELOPMENT 206
16.23 PROVISION HEALTHCARE 207
16.23.1 COMPANY SNAPSHOT 207
16.23.2 PRODUCT PORTFOLIO 207
16.23.3 RECENT DEVELOPMENT 207
16.24 RAYSEARCH LABORATORIES 208
16.24.1 COMPANY SNAPSHOT 208
16.24.2 REVENUE ANALYSIS 208
16.24.3 PRODUCT PORTFOLIO 209
16.24.4 RECENT DEVELOPMENT 209
16.25 SIT - S.I.T. SORDINA IORT TECHNOLOGIES S.P.A. 210
16.25.1 COMPANY SNAPSHOT 210
16.25.2 PRODUCT PORTFOLIO 210
16.26 SUMITOMO HEAVY INDUSTRIES, LTD. 211
16.26.1 COMPANY SNAPSHOT 211
16.26.2 REVENUE ANALYSIS 211
16.26.3 PRODUCT PORTFOLIO 212
16.26.4 RECENT DEVELOPMENT 212
16.27 VIEWRAY TECHNOLOGIES, INC. (VIEWRAY) 213
16.27.1 COMPANY SNAPSHOT 213
16.27.2 RECENT FINANCIALS 213
16.27.3 PRODUCT PORTFOLIO 214
16.27.4 RECENT DEVELOPMENT 214
16.28 XOFT, A SUBSIDIARY OF ICAD, INC. 215
16.28.1 COMPANY SNAPSHOT 215
16.28.2 REVENUE ANALYSIS 215
16.28.3 PRODUCT PORTFOLIO 216
16.28.4 RECENT DEVELOPMENT 216
16.29 ZEISS INTERNATIONAL 217
16.29.1 COMPANY SNAPSHOT 217
16.29.2 PRODUCT PORTFOLIO 217
16.29.3 RECENT DEVELOPMENT 217
17 QUESTIONNAIRE 218
18 RELATED REPORTS 221
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
